Icon

ALECENSA (nda208434)- (EQ 150MG BASE)

ALECTINIB HYDROCHLORIDE HOFFMANN-LA ROCHE
EQ 150MG BASE
Yes No
2035-Apr-24 2020-Dec-11
2022-Dec-11 None
None No
ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
0 0 0
Total Other Developers 8
Drugs with Suitability No
EQ 150MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.